fda approv ahead schedul without black
messag ayvakit avapritinib obtain full fda approv
treatment patient unresect metastat pdgfra gastrointestin stromal
tumor gist approv consist investor expect albeit
slightli earlier time pdufa notabl fda label includ
black box safeti warn remov small overhang view investor
concern possibl given ayvakit intracrani bleed cognit
impair side effect updat estim account fda approv
maintain buy pt
receiv full fda approv ayvakit avapritinib pdgfra gist earlier
expect without black box safeti warn full approv came ahead
februari pdufa date lack black box safeti warn increment
posit view given investor debat cognit effect intracrani bleed
toxic observ ayvakit
ayvakit well posit therapi compel clinic profil
pdgfra gist caveat potenti price market access dynam model
peak annual us sale slow ramp assum elig pdgfra
gist patient repres annual gist us receiv treatment
remain therapi month management commentari question call focus
commerci landscap given per month wac price potenti gross-to-net
adjust light numer patient support program barrier patient identif
us patient year indic potenti implic mgmt-anticip
payer mix medicar commerci
top line phase voyag result earli next potenti key catalyst
gist recal fda previous split ayvakit pdgfra
kit gist nda file link push latter potenti approv fda
await top line voyag data supplement file
modestli adjust near-term forecast increas po
previous assum ayvakit penetr pdgfra patient previous
result sale attribut ayvakit pdgfra gist
maintain buy pt ayvakit approv transit
fully-integr commerci pipelin execut key
view see preview believ avapritinib continu well posit
indol advanc sm given promis initi data compel overal risk/benefit
respect sequenc dcph ripretinib kit gist furthermor
pralsetinib look similar differ competitor selpercatinib may
captur share ret nsclc given like launch mere month
selpercatinib link final engin remain confid abil
gener promis precis medicin asset highlight day link
page analyst certif import disclosur
valuat risk
valu per share use dcf base valuat method
valuat includ probability-adjust cash flow deriv compani pipelin
includ avapritinib use discount rate termin growth rate
appli termin year post-assum gener entri lead pipelin candid
risk valuat includ regulatori commerci setback
potenti emerg new competitor lower product sale expect
page analyst certif import disclosur
total cost expens
interest incom net
loss extinguish debt
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
